David co-founded EyeBio with Anthony P. Adamis, M.D., in August 2021. Today he holds the title of EyeBio Co-founder, President, and Chief Executive Officer (CEO). David is also a Venture Partner at SV Health Investors and is Co-Founder and former CEO and Executive Chairman of Iveric Bio (previously Ophthotech). David served as Chairman of Iveric Bio’s board of directors from 2007 to 2017, as CEO from 2013 to 2017, and as Executive Chairman from 2017 to 2021. Under his leadership, Iveric Bio entered into a partnership with Novartis that, at the time, was one of the largest ex-U.S. partnering transactions in biotechnology industry history.

David has expansive medical, drug development, and commercial experience in ophthalmology. His expertise is highly sought after, and he has served on the boards of approximately 20 companies, both public and private. In addition to co-founding EyeBio and Iveric Bio, David co-founded Eyetech Pharmaceuticals Inc. and served as its CEO and member of the board of directors from 2000 until the company’s acquisition by OSI Pharmaceuticals, Inc. in November 2005.

Prior to co-founding Eyetech Pharmaceuticals, David was a professor and Chairman of the Department of Ophthalmology at New York University School of Medicine. David received a B.S. from Yale College and an M.D. from Johns Hopkins Medical School. He completed his ophthalmology residency at Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

Sarah brings a deep background in life sciences strategy, development, and commercialization to her role as Chief Operating Officer at EyeBio. Prior to joining EyeBio, Sarah served as Vice President of Translation at Touchlight Genetics where she managed a portfolio of product and platform R&D programs. While at Touchlight Genetics, Sarah led a vaccine clinical development program in partnership with Cancer Research United Kingdom (CRUK) and was part of the fundraising team that saw the company transition into its commercial phase.

Previously, Sarah was a Strategy Consultant on the Life Sciences team at L.E.K. Consulting, where she worked with biotech and pharmaceutical companies on a range of strategy and mergers and acquisition (M&A) projects.

Sarah received a B.Eng. (Hons) in Biomedical Engineering and a B.A. in French and Statistics from the University of Auckland, New Zealand.

Jonathan joined EyeBio as Chief Medical Officer. A noted retina specialist with several leadership positions in the field of vitreoretinal surgery, he is currently Chairman of the Department of Ophthalmology at Rutgers Robert Wood Johnson Medical School, where he serves as Clinical Professor. For the past fifteen years he has held the positions of Review Article Section Editor and Assistant Editor for the standard scientific journal for the field, RETINA: The Journal of Retinal and Vitreous Diseases. An active researcher, Jonathan has published more than 95 peer-reviewed papers, and he routinely lectures on his original research and the development of new approaches to vitreoretinal diseases at major scientific meetings.

Jonathan has an extensive history of working with biotechnology startups. He has been a member of the scientific advisory boards of Acuity Pharmaceuticals and OPKO and has served on the data safety monitoring boards of Neurotech and Clearside Bio. He has also had long-term strategic consulting relationships with Neovista, Ophthotech, and Panoptica.

Jonathan received his B.A. from the University of Pennsylvania and his Medical Doctor degree from the State University of New York at Stony Brook, where he was accepted into the Alpha Omega Alpha Honor Society. Jonathan then returned to the University of Pennsylvania’s Scheie Eye Institute for residency training and completed his vitreoretinal fellowship at William Beaumont Hospital in Royal Oak, Mich. He has been a practicing clinician since 2004.

Divya joined EyeBio as Senior Vice President of Clinical Development. She is responsible for the company’s clinical development strategy and execution. 

Prior to joining EyeBio, Divya held various roles at the United Kingdom’s (UK) National Institute for Health Research (NIHR) beginning in 2007. Her most recent role at NIHR was the Clinical Research Network’s Director of Business Development and Marketing, where she led a team responsible for increasing investment into UK-based health and social care research from both non-commercial and commercial research sponsors. 

In 2020, Divya was seconded to the UK Vaccines Taskforce (VTF), which was set up in response to the COVID-19 pandemic to lead the UK’s search for a safe and effective vaccine. In that capacity she was responsible for supporting global pharmaceutical companies’ efforts to rapidly generate the evidence required for marketing authorization of COVID-19 vaccines and played a pivotal role in conceptualizing and developing the National Health Service (NHS) Vaccine Research Registry. 

Divya holds a B.Sc. in Psychology from Royal Holloway at the University of London, and was awarded an India academic scholarship to complete a MRes degree at the University of Birmingham, UK.  

Paul joined EyeBio as Senior Vice President of Chemistry, Manufacturing, and Controls (CMC). He is responsible for early candidate selection and development of EyeBio’s large-molecule portfolio.

Paul has more than 35 years of experience in the biotechnology industry. With over 50 peer-reviewed publications, he is an expert in antibody drug development and expression. Previously, Paul was Senior Director and Head of Antibody Biology at UCB, where he was responsible for the company’s early antibody pipeline and oversaw the transition of UCB’s novel biological entities (NBEs) from the research stage into development. While at UCB, Paul was actively involved in the development of both Evenity® (romosozumab) and Bimzelx® (bimekizumab).

Paul received B.Sc. in Biochemistry from Southampton University, and he completed his Ph.D. at Sheffield University.